Avidity Maturation following Immunization with Two Human Cytomegalovirus (CMV) Vaccines: A Live Attenuated Vaccine (Towne) and a Recombinant Glycoprotein Vaccine (gB/MF59)

Viral Immunology

Volumn 16, Issue 4, 2003, Pages 491-500

  Marshall, Beth C ^a   Adler, Stuart P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; RECOMBINANT GLYCOPROTEIN B VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; MALE; SINGLE DRUG DOSE; VIRUS STRAIN; WILD TYPE;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5;

EID: 0347362589     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/088282403771926319     Document Type: Article

References (41)

1. Adler, SP. 1994. Development and clinical status of cytomegalovirus vaccines. Clin. Immunother. 2:1-6.
2. Adler, S.P., S.H. Hempfling, S.E. Starr, et al. 1998. Evaluation of the safety and immunogenicity of the Towne strain of cytomegalovirus among women of childbearing age and children. Pediatr. Infect. Dis. J. 17:200-206.
3. Adler, S.P. and M. McVoy. 1986. Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for and effect resulting from strain heterogeneity. J. Clin. Microbiol. 24:870-872
4. Avanzini, M.A., P. Pignatti, G. Chirico, et al. 1998. Placental transfer favours high avidity IgG antibodies. Acta Paediatr. 87:180-185.
5. Baccard-Longere. M., F. Freymuth, D. Cointe, et al. 2001. Multicenter evaluation of a rapid and convenient method for determination of cytomegalovirus immunoglobulin G avidity. Clin. Diag. Lab. Immun. 8:429-431.
6. Blackburn, N.K., T.G. Besselaar, B.D. Schoub, et al. 1991. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity. J. Med. Virol. 33:6-9.
7. Bodeus, M., P. Beulne and P. Goubau. 2001. Ability of three IgG-avidity assays to exclude recent cytomegalovirus infection. Eur. J. Clin. Microbiol. Infect. Dis. 20:248-252.
8. Bodeus, M., and P. Goubau. 1999. Predictive value of maternal-IgG avidity for congenital human cytomegalovirus infection. J. Clin. Virol. 12:3-8.
9. Bodeus, M., S. Feyder, and P. Goubau. 1998. Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infection in pregnant women. Clin. Diagn. Virol. 9:9-16.
10. Boppana, S.B., and W.J. Britt. 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 171:1115-1121.
11. Breukels, M.A., E Jol-van der Zijde, M.J. van Tol, et al. 2002. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin. Infect. Dis. 34:191-197.
12. de Souza, V.A., C.S. Pannuti, L.M. Sumita, et al. 1997. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J. Med. Virol. 52:275-279.
13. Fowler, K.B., S. Stagno, R.F. Pass, et al. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:663-667.
14. French, D., R. Laskow, and M. Scharff. 1989. The role of somatic hypermutation in the generation of antibody diversity. Science 244:1152-1157.
15. Frey, S.E., C. Harrison, R.F. Pass, et al. 1999. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein b subunit vaccine. J. Infect. Dis. 180:1700-1703.
16. Goldblatt, D., ARJPM Pinto Vaz, and E. Miller. 1998. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1112-1115.
17. Grangeot-Keros, L., M.J. Mayaux, P. Lebon, et al. 1997. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary cmv infection in pregnant women. J. Infect. Dis. 175:944-946.
18. Griffiths, P.D., A. McLean, and V.C. Emery. 2001. Encouraging prospects for immunization against primary cytomegalovirus infection. Vaccine 19:1356-1362.
19. Hedman, K., J. Hietala, A. Tiilikainen, et al. 1989. Maturation of immunoglobulin g avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (Avidity-ELISA) and by haemolysis typing. J. Med. Virol. 27:293-298
20. Lafarga, B., F.J. Noguera, M. Bolanos, et al. 1997. Performance of the IgG avidity test in patients with cytomegalovirus disease. Enferm. Infecc. Microbiol. Clin. 15:190-195.
21. Lazzarotto, T., P. Spezzacatena, S. Varani, et al. 1999. Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin. Diag. Lab. Immun. 6:127-129.
22. Lazzarotto, T., P. Spezzacatena, P. Pradelli, et al. 1997. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin. Diag. Lab. Immunol. 4:469-473.
23. Lazzarotto, T., S. Varani, P. Spezzacatena, et al. 2000. Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus. Viral Immunol. 13:137-141.
24. Longworth, E., R. Borrow, D. Goldblatt, et al. 2002. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20:2592-2596.
25. Macdonald, R.A., C.S. Hosking, and C.L. Jones. 1988. The measurement of relative antibody affinity by ELISA using isothiocyanate elution. J. Immunol. Methods. 106:191-194.
26. Marshall, G.S., M. Li, G.G. Stout, et al. 2000. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immun. 13:329-341.
27. Pass, R.F., A.M. Duliege, S. Boppana, et al. 1999. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein b and a new adjuvant. J. Infect. Dis. 180:970-975.
28. Pichichero, M.E., T. Voloshen, D. Zajac, et al. 1999. Avidity maturation of antibody to Haemophilus influenzae type b (Hib) after immunization with diphtheria-tetanus-acellular pertussis-Hib-Hepatitis B combined vaccine in infants. J. Infect. Dis. 180:1390-1393.
29. Plotkin, S.A., R. Higgins, J.B. Kurtz, et al. 1994. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58:1176-1178.
30. Plotkin, S.A., J. Farquhar, and E. Hornberger. 1976. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J. Infect. Dis. 134:470-475.
31. Prince, H.E., and A.L. Leber. 2002. Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels. Clin. Diagn. Lab. Immunol. 9:824-827.
32. Robbins, J.B., R. Schneerson, and S.C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
33. Ruellan-Eugene, G., P. Barjot, M. Campet, et al. 1996. Evaluation of virological procedures to detect fetal human cytomegalovirus infection: avidity of IgG antibodies, virus detection in amniotic fluid and maternal serum. J. Med. Virol. 50:9-15.
34. Schlesinger, Y., and D.M. Granoff. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267:1489-1494.
35. Siekevitz, M., C. Koch, K. Rajewsky, et al. 1987. Analysis of somatic mutation and class switching in naive and memory B cells generating adoptive primary and secondary responses. Cell 48:757-770.
36. Sipewa, M.J., P. Goubau, and M. Bodeus. 2002. Evaluation of a cytomegalovirus glycoprotein B recombinant enzyme immunoassay to discriminate between a recent and a past infection. J. Clin. Microbiol. 40:3689-3693.
37. Spaete, R.R., A. Saxena, P.I. Scott, et al. 1990. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain for Towne. J. Virol. 64:2922-2931.
38. Usinger, W.R., and A.H. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366-2370.
39. Vermont, C.L., H.H. van Dijken, C.J.P. van Limpt, et al. 2002. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningoccocal B outer membrane vesicle vaccine. Infect. Immun. 70:584-590.
40. Wang, J.B., S.P. Adler, S.H. Hempfling, et al. 1996. Mucosal antibodies to CMV glycoprotein B occur following both natural infection and immunization with human cytomegaloviral vaccines. J. Infect Dis. 174: 397-392.
41. Wuorimaa, T., R. Dagan, M. Vakevainen, et al. 2001. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184:1211-1215.